BGB-43395: A Selective CDK4 Inhibitor in Clinical Development for Cancer Therapy

1. Executive Summary

BGB-43395 is an orally administered, highly potent, and selective small-molecule inhibitor of Cyclin-Dependent Kinase 4 (CDK4) currently under development by BeiGene.[1] The investigational agent is in Phase 1 clinical trials, with a primary focus on hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. Its development program also includes exploration in other advanced solid tumors.[1] A key differentiating characteristic of BGB-43395 is its high selectivity for CDK4 over Cyclin-Dependent Kinase 6 (CDK6). This selectivity is designed to mitigate CDK6-associated toxicities, particularly neutropenia, a common dose-limiting side effect of currently approved dual CDK4/6 inhibitors. An improved tolerability profile could potentially allow for more sustained target inhibition, which may, in turn, lead to enhanced therapeutic outcomes.[8] BeiGene has signaled intentions for an accelerated clinical advancement pathway, including the potential initiation of Phase 3 trials.[10]

The strategic emphasis on CDK4 selectivity underscores a deliberate effort to address a well-recognized limitation of existing therapies in this class. Approved dual CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, while effective, frequently cause neutropenia due to their inhibitory action on CDK6.[8] This hematological toxicity can necessitate dose reductions or treatment interruptions, potentially compromising the continuous drug exposure required for optimal efficacy. BGB-43395's design aims to circumvent this by selectively targeting CDK4, the kinase predominantly implicated in the proliferation of HR+/HER2- breast cancer cells, while sparing CDK6. If this selective inhibition translates to a clinically meaningful reduction in neutropenia, it could allow for more consistent administration of BGB-43395 at therapeutically effective doses. Such sustained CDK4 inhibition could theoretically lead to improved clinical benefits, such as longer progression-free survival or deeper tumor responses, thereby offering a significant advantage over current standards of care.

The rapid progression of BGB-43395 through development milestones—from preclinical evaluation to the initiation of the first human trial in December 2023 [10] and BeiGene's stated ambition to commence Phase 3 trials as early as the fourth quarter of 2025 [10]—suggests considerable internal confidence in the molecule's profile. This accelerated timeline is likely driven by a combination of compelling preclinical data and the competitive dynamics within the oncology landscape, notably the parallel development of other selective CDK4 inhibitors like Pfizer's atirmociclib.[10] Furthermore, BeiGene's internal sales projections, reportedly in the range of $5 billion for BGB-43395 [10], highlight the company's significant expectations for the drug and provide a strong rationale for an assertive investment and development strategy. This rapid advancement may also imply that early, albeit not fully public, clinical signals are encouraging, or that the strategic need to establish a competitive foothold in the market dictates an accelerated pace.

2. Introduction to BGB-43395

BGB-43395 is an investigational therapeutic agent developed by BeiGene [1], a global oncology company dedicated to the discovery, development, and commercialization of innovative and accessible cancer treatments.[11] BeiGene's research and development pipeline encompasses a diverse portfolio of oncology candidates.[16]

BGB-43395 is classified as a small molecule drug [11] and functions as an antineoplastic agent.[1] Its specific therapeutic mechanism involves the inhibition of Cyclin-Dependent Kinase 4 (CDK4).[1]

The rationale for the development of BGB-43395 stems from the established clinical success of dual CDK4 and CDK6 inhibitors, which, in combination with endocrine therapy, have become a cornerstone in the treatment of HR+/HER2- breast cancer.[8] Despite their efficacy, these dual inhibitors are commonly associated with dose-limiting neutropenia. This adverse event is primarily attributed to the inhibition of CDK6, which plays a role in hematopoietic cell proliferation.[8] Such toxicity often necessitates interruptions in treatment or reductions in dosage, which can compromise the ability to maintain sustained inhibition of CDK4. Continuous CDK4 inhibition is considered crucial for maximizing therapeutic efficacy in HR+/HER2- breast cancer, as CDK4 is the principal kinase driving cell cycle progression in this cancer subtype.[8] BGB-43395 has been specifically engineered as a CDK4 selective inhibitor. The objective of this selectivity is to minimize the inhibition of CDK6, thereby reducing the incidence and severity of neutropenia. This approach aims to allow for more consistent and potentially higher levels of CDK4 target engagement, which could translate into improved clinical outcomes for patients.[8]

This development strategy positions BGB-43395 not merely as an addition to the existing class of CDK inhibitors but as a potentially refined therapeutic option. It represents a targeted effort to improve upon current standards of care by addressing a specific, well-documented limitation. The success of dual CDK4/6 inhibitors has validated the CDK4/6 pathway as a critical therapeutic target in HR+/HER2- breast cancer. However, the associated neutropenia linked to CDK6 inhibition presents a clear opportunity for pharmacological improvement. BeiGene's focused development of a CDK4-selective agent is a direct attempt to overcome this particular challenge. If this approach proves successful in clinical trials, BGB-43395 could offer a superior therapeutic index, defined by a more favorable balance of efficacy and toxicity, making it a potentially more attractive treatment choice for both patients and clinicians.

Furthermore, the selective inhibition of CDK4, coupled with a potentially improved tolerability profile, may offer advantages beyond reduced neutropenia. Sustained target inhibition might address other unmet needs, such as delaying or overcoming acquired resistance to dual CDK4/6 inhibitors. Moreover, a less myelosuppressive CDK4 inhibitor could be more amenable to combination therapies with other anticancer agents, particularly those that may also have myelosuppressive effects, thereby expanding its therapeutic utility. While the primary clinical focus for BGB-43395 is HR+/HER2- breast cancer, its mechanism of action—targeting CDK4-dependent cell proliferation—suggests potential applicability in other solid tumors where CDK4 dysregulation is a contributing factor. Preclinical studies have indicated anti-proliferative activity in various cancer cell lines beyond breast cancer, including prostate, ovarian, endometrial, and lung cancer.[8] Consistent with this, BeiGene's early-phase clinical trials are designed to explore BGB-43395's activity in a range of advanced solid tumors, indicating a broader exploratory strategy.[4] Successful demonstration of efficacy in these other CDK4-dependent tumor types could significantly expand the drug's market potential.

3. Mechanism of Action

The primary molecular target of BGB-43395 is Cyclin-Dependent Kinase 4 (CDK4).[1] CDK4 is a serine/threonine kinase that, in complex with D-type cyclins (Cyclin D1, D2, D3), forms an active holoenzyme. This complex is a critical regulator of cell cycle progression, specifically controlling the transition from the G1 (first gap or growth) phase to the S (DNA synthesis) phase.[8]

Upon oral administration, BGB-43395 functions by selectively inhibiting the enzymatic activity of the CDK4/Cyclin D complex.[2] This inhibition prevents the subsequent phosphorylation of key CDK4 substrates, most notably the retinoblastoma tumor suppressor protein (Rb), during the early G1 phase of the cell cycle.[2] In its hypophosphorylated state, Rb binds to and sequesters E2F transcription factors. Phosphorylation of Rb by CDK4/Cyclin D complexes leads to the release of E2F proteins, which then activate the transcription of genes necessary for DNA replication and S-phase entry. By preventing Rb phosphorylation, BGB-43395 maintains Rb in its active, E2F-binding state. This action effectively blocks the G1-S phase transition, leading to cell cycle arrest in the G1 phase.[2] The ultimate consequence of this G1 arrest is the suppression of DNA replication and, therefore, the inhibition of tumor cell proliferation.[2] Preclinical studies have corroborated this mechanism, demonstrating that BGB-43395 induces G1 cell cycle arrest and promotes cellular senescence in HR+ breast cancer cell lines.[8]

A defining feature of BGB-43395 is its high selectivity for CDK4 over CDK6 and other members of the CDK enzyme family.[8] Biochemical assays have quantified the potency of BGB-43395 against CDK4, revealing an half-maximal inhibitory concentration (IC50) of 0.91±0.42 nM (n=3) under 100 µM ATP conditions.[8] While the precise IC50 value for CDK6 is not explicitly stated in the summarized materials, the repeated emphasis on high selectivity implies a significantly weaker inhibition of CDK6. This selectivity was further confirmed against a broad panel of 372 other kinases, where BGB-43395 showed favorable selectivity when tested at a concentration 100 times its CDK4 IC50.[8] This pronounced selectivity for CDK4 is central to the drug's development rationale, as it is intended to minimize the adverse events associated with CDK6 inhibition, primarily neutropenia.[8]

It is important to address a point of potential confusion regarding the drug's targets. One data source [12] suggests that BGB-43395 targets both CDK4 and Human Epidermal Growth Factor Receptor 2 (HER2). However, this assertion is an outlier when compared to the predominant information from BeiGene's own scientific presentations [8] and other specialized drug databases [1], all of which consistently describe BGB-43395 as a selective CDK4 inhibitor. The primary focus of its clinical development is in HR+/HER2- breast cancer, where CDK4 is the established therapeutic target for this class of agents. While some clinical trials, such as NCT06756932, are exploring BGB-43395 in HER2-positive breast cancer populations [1], this is likely to evaluate the efficacy of CDK4 inhibition within that specific breast cancer subtype, rather than indicating a direct antagonistic effect of BGB-43395 on HER2. Therefore, this report will proceed based on the extensive evidence supporting BGB-43395's mechanism as a selective CDK4 inhibitor.

The mechanistic advantage of BGB-43395, centered on its CDK4 selectivity, holds the promise of an enhanced therapeutic index. This index, a measure of a drug's beneficial effects at a therapeutic dose versus its harmful effects, could be significantly improved if BGB-43395 clinically demonstrates a reduction in neutropenia while retaining or even improving the anti-tumor efficacy driven by CDK4 inhibition. Current dual CDK4/6 inhibitors have a therapeutic window constrained by CDK6-mediated toxicities.[8] By aiming to decouple the desired anti-cancer effect (CDK4 inhibition) from a major dose-limiting toxicity (CDK6 inhibition), BGB-43395 could allow for more consistent drug administration, potentially at higher relative exposures to the CDK4 target. This, in turn, could lead to more profound and durable responses in cancer patients and an improved quality of life due to fewer side effects.

Furthermore, while the primary effect of CDK4 inhibition is on tumor cell cycle progression, the differential impact on the tumor microenvironment due to sparing CDK6 activity warrants consideration. CDK6 is known to have roles in the proliferation of hematopoietic cells and in T-cell function. By selectively inhibiting CDK4 and sparing CDK6, BGB-43395 might cause less disruption to normal hematopoietic processes and T-cell homeostasis compared to dual inhibitors. This could be advantageous not only for reducing direct hematological toxicities but also for potentially preserving or enhancing immune competence within the tumor microenvironment. While speculative at this stage and requiring further investigation, such an effect could be beneficial, particularly if BGB-43395 were to be explored in combination with immunotherapies in the future.

4. Preclinical Development and Findings

The preclinical development of BGB-43395 has yielded a substantial body of data supporting its potential as a highly potent and selective CDK4 inhibitor with a favorable safety profile. These studies have been crucial in establishing the scientific rationale for its advancement into clinical trials.

4.1 In Vitro Studies

In vitro evaluations have consistently highlighted the potency and selectivity of BGB-43395.

• Potency: Biochemical assays established a high potency for BGB-43395 against CDK4, with a reported IC50 value of 0.91±0.42 nM (n=3) when tested under 100 µM ATP conditions.[8] Comparative studies indicated that BGB-43395 exhibits superior kinase inhibition against CDK4 when compared to currently approved dual CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—as well as the investigational selective CDK4 inhibitor atirmociclib (PF-07220060).[8]
• Selectivity: A defining characteristic of BGB-43395 is its pronounced selectivity for CDK4 over CDK6 and other CDK family kinases. This selectivity was demonstrated at the biochemical level. Furthermore, when assessed against a broad panel of 372 other kinases at a concentration 100 times its CDK4 IC50, BGB-43395 maintained a favorable selectivity profile.[8] This high degree of selectivity is fundamental to its anticipated improved safety margin, particularly concerning CDK6-mediated toxicities.
• Cellular Activity: The biochemical potency and selectivity of BGB-43395 translated into robust effects in cellular assays:
• RB1 Phosphorylation Inhibition: In CDK4-dependent HR+/HER2- breast cancer cell lines, including MCF7, T47D, and ZR-75-1, BGB-43395 demonstrated more potent inhibition of the phosphorylation of the Retinoblastoma 1 protein at serine 780 (pRB1-S780) compared to atirmociclib and the approved dual CDK4/6 inhibitors.[8] This finding confirms effective engagement of the CDK4 target and modulation of its critical downstream signaling pathway within a relevant cellular context.
• Anti-proliferative Effects: As a consequence of its potent CDK4 inhibition, BGB-43395 exhibited greater anti-proliferative activity in HR+/HER2- breast cancer cell lines. Importantly, its anti-proliferative effects were also observed in other cancer cell lines, including those derived from prostate, ovarian, endometrial, and lung cancers, suggesting a potential for broader therapeutic application in various CDK4-dependent malignancies.[8]
• Cell Cycle Arrest and Senescence: Consistent with its mechanism of action as a CDK4 inhibitor, BGB-43395 was shown to induce G1 phase cell cycle arrest and promote cellular senescence in HR+ breast cancer cell lines (MCF7, T47D) in a dose-dependent manner.[8]

4.2 In Vivo Efficacy (Animal Models)

The promising in vitro profile of BGB-43395 was further substantiated in in vivo animal models.

• Pharmacodynamics: Studies in mouse xenograft models utilizing MCL Jeko-1 cells and HR+HER2- MCF7 cells demonstrated that BGB-43395 monotherapy led to significant and dose-dependent inhibition of RB1 phosphorylation within the tumor tissues.[8] This confirmed that BGB-43395 effectively engages its target and modulates the CDK4 pathway in a live animal system.
• Antitumor Activity:
• Monotherapy: In Jeko-1 xenograft models, BGB-43395 monotherapy resulted in significant tumor growth inhibition (TGI). Notably, its anti-tumor activity was reported to be greater than that of palbociclib when administered at clinically relevant doses.[9]
• Combination Therapy: When BGB-43395 was combined with fulvestrant, a standard endocrine therapy, it demonstrated significantly greater TGI in the HR+HER2- MCF7 xenograft model compared to the combination of palbociclib and fulvestrant.[9] A particularly noteworthy finding emerged from a patient-derived xenograft (PDX) model established from an HR+ breast cancer patient who had previously progressed on palbociclib treatment. In this resistant model, the combination of BGB-43395 and fulvestrant still achieved significant TGI.[8] This suggests that BGB-43395 might possess activity even in tumors that have developed resistance to existing dual CDK4/6 inhibitors.

4.3 Nonclinical Safety and Toxicology

Preclinical safety evaluations have indicated that BGB-43395 is generally well-tolerated.[8] A critical aspect of these nonclinical toxicity studies was the observation that BGB-43395 did not cause concerning neutropenia or gastrointestinal toxicity issues.[8] This finding is paramount as it supports the central hypothesis that the selective inhibition of CDK4, while sparing CDK6, can translate into an improved safety profile, especially concerning myelosuppression which is a common dose-limiting toxicity for dual CDK4/6 inhibitors. Early clinical data from the Phase 1a portion of the NCT06120283 trial, as reported in a Synapse drug profile, appear to align with these preclinical safety observations, noting that hematological adverse events such as neutropenia (4.6%) and anemia (12.3%) were relatively uncommon and predominantly low-grade, while gastrointestinal side effects were more frequently observed.[11]

The comprehensive preclinical data package for BGB-43395 provides a robust foundation for its clinical advancement. The demonstration of superior potency against CDK4, high selectivity over CDK6 and other kinases, desired downstream cellular effects (pRb inhibition, cell cycle arrest, anti-proliferation), significant in vivo pharmacodynamic activity, and compelling anti-tumor efficacy in various models (including monotherapy, combination therapy, and a palbociclib-resistant PDX model) collectively underscore its therapeutic potential. This is further strengthened by a favorable preclinical safety profile, particularly the observed sparing of CDK6-mediated neutropenia, which appears to be translating into early clinical findings.

The efficacy demonstrated in the palbociclib-progressor PDX model [8] is of particular significance. Acquired resistance to currently available CDK4/6 inhibitors is a major clinical challenge. If BGB-43395 can indeed show activity in patients whose tumors have developed resistance to dual CDK4/6 inhibitors, it would address a substantial unmet medical need and could offer a valuable new therapeutic option. The mechanisms underlying this potential activity in resistant settings—whether due to overcoming specific resistance pathways or achieving more sustained and profound target inhibition due to better tolerability—warrant further investigation in clinical trials.

The primary HR+/HER2- breast cancer indication is clearly driven by CDK4 dependency. The observed anti-proliferative activity of BGB-43395 in other CDK4-dependent cancer cell lines, such as prostate, ovarian, endometrial, and lung cancer [8], suggests that CDK4 dependency could serve as a biomarker to identify patient populations in other tumor types who might benefit from this selective inhibitor. This opens avenues for broader clinical exploration beyond breast cancer.

The following table summarizes key preclinical findings for BGB-43395:

Table 1: Summary of Key Preclinical Data for BGB-43395

Parameter	BGB-43395 Result	Comparator Result(s)	Cell Line/Model	Key Implication	Source Snippet(s)
Biochemical Potency	CDK4 IC50: 0.91±0.42 nM (n=3)	Superior to palbociclib, ribociclib, abemaciclib, atirmociclib	Biochemical assay (100 µM ATP)	High intrinsic potency against target kinase	8
Biochemical Selectivity	Highly selective for CDK4 over CDK6 and other CDK family kinases; favorable vs. 372 other kinases at 100x CDK4 IC50	Not explicitly quantified against CDK6 in summaries, but implied high	Biochemical assays	Potential for reduced CDK6-mediated toxicity (e.g., neutropenia)	8
Cellular pRB1 Inhibition	More potent inhibition of pRB1-S780	More potent than atirmociclib & approved CDK4/6 inhibitors	HR+HER2- BC cells (MCF7, T47D, ZR-75-1)	Effective target engagement and pathway modulation in cancer cells	8
Cellular Anti-proliferation	Greater anti-proliferative activity	Compared to atirmociclib & approved CDK4/6 inhibitors	HR+HER2- BC cells; also prostate, ovarian, endometrial, lung cancer cells	Broad anti-cancer activity in CDK4-dependent cell lines	8
Cellular Effects	Induces G1 cell cycle arrest and cellular senescence	N/A	HR+ BC cells (MCF7, T47D)	Consistent with CDK4 inhibition mechanism	8
In Vivo PD (Tumor)	Significant, dose-dependent inhibition of RB1 phosphorylation	N/A	Jeko-1, MCF7 mouse xenografts	Confirms target engagement in vivo	8
In Vivo Efficacy (Mono)	Significant TGI	Greater TGI than palbociclib at clinically relevant doses	Jeko-1 xenograft	Potent monotherapy anti-tumor effect	9
In Vivo Efficacy (Combo)	Significant TGI with fulvestrant	Greater TGI than palbociclib + fulvestrant	MCF7 xenograft	Enhanced efficacy with endocrine therapy	9
In Vivo Efficacy (Resistant)	Significant TGI with fulvestrant	N/A	Palbociclib-progressor PDX model	Potential activity in acquired resistance settings	8
Nonclinical Safety	Well tolerated; no concerning neutropenia or GI toxicity issues	Implied better profile than dual CDK4/6 inhibitors	Nonclinical toxicity studies	Supports hypothesis of improved safety due to CDK4 selectivity; early clinical data appears consistent 11	8

5. Clinical Development Program

BGB-43395 is currently advancing through Phase 1 of clinical development.[1] BeiGene has articulated a strategy for rapid progression, with aspirations to initiate Phase 3 trials as early as the fourth quarter of 2025.[10] The clinical program is designed to evaluate BGB-43395 both as a monotherapy and in combination with established endocrine therapies, such as fulvestrant and letrozole. The primary patient populations under investigation are those with HR+/HER2- breast cancer, alongside an exploratory arm for other advanced solid tumors.[4]

5.1 Detailed Review of Key Clinical Studies

NCT06120283 (Study ID: BGB-43395-101)

• Official Title: "A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4...source Advanced Solid Tumors".[6]
• Phase: 1a (Dose Escalation) / 1b (Dose Expansion).[6]
• Status: Actively recruiting participants.[4] The study commenced in December 2023, with the last update noted on April 9, 2025.[18]
• Purpose: The Phase 1a portion aims to determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and the Recommended Dose for Expansion (RDFE) of BGB-43395. The Phase 1b portion will further evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity (including Objective Response Rate (ORR), Duration of Response (DOR), Progression-Free Survival (PFS), Disease Control Rate (DCR), and Clinical Benefit Rate (CBR)) of BGB-43395 as a monotherapy and in combination regimens.[6]
• Patient Population:
• Phase 1a: Enrolls adults (≥18 years) with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors considered to be associated with CDK4 dependency. This includes HR+ breast cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), among others. Participants must have received, or been refractory to or intolerant of, all standard-of-care therapies. For patients with HR+ breast cancer in regions where CDK4/6 inhibitors are approved and available, at least two prior lines of treatment, including endocrine therapy and a CDK4/6 inhibitor, are required.[7]
• Phase 1b: Focuses on selected tumor cohorts, prominently featuring HR+/HER2- breast cancer. For HR+/HER2- breast cancer patients in regions where CDK4/6 inhibitors are approved, they must have received at least one line of therapy for advanced disease, which includes endocrine therapy and a CDK4/6 inhibitor. These patients can have received up to two lines of prior cytotoxic chemotherapy for advanced disease.[7]
• Interventions: BGB-43395 is administered orally. Part A of the study evaluates BGB-43395 as monotherapy. Combination arms include BGB-43395 with fulvestrant (administered via intramuscular injection) or BGB-43395 with letrozole (administered orally).[18] The study employs sequential cohorts with increasing dose levels of BGB-43395 to establish the optimal dosing regimen.[21]
• Key Eligibility Criteria: Participants must have measurable disease according to RECIST v1.1 criteria and an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1, along with adequate organ function. Female participants with metastatic HR+/HER2- breast cancer must be postmenopausal or receiving ovarian function suppression. Key exclusion criteria include prior therapy with a selective CDK4 inhibitor (though prior dual CDK4/6 inhibitor therapy is permitted and, in some cohorts, required), known leptomeningeal disease or uncontrolled/untreated brain metastases, other malignancies within the preceding three years (with specific exceptions), uncontrolled diabetes, and active infections requiring systemic treatment.[7]
• Outcome Measures:
• Primary (Phase 1a): MTD or MAD of BGB-43395; RDFE of BGB-43395. These are assessed over a timeframe of up to approximately 30 months.[21]
• Secondary (Selected, Phase 1b/Overall): ORR, DOR, PFS, DCR, CBR, number of participants experiencing adverse events (AEs) and serious adverse events (SAEs), and PK parameters (Cmax, Ctrough, AUC, t1/2) of BGB-43395 and its metabolite(s). Efficacy outcomes are assessed up to approximately 30 months, while PK parameters are typically assessed up to Cycle 7 Day 1.[21]
• Locations: The trial is being conducted at multiple sites globally, including in Australia (New South Wales, South Australia, Victoria), the USA (e.g., Duke Cancer Institute), and other international locations.[4] The estimated enrollment is 79 participants.[18]
• Reported Data: Preliminary safety and pharmacology data from this study were presented at the San Antonio Breast Cancer Symposium (SABCS) in 2024.[8] A Synapse drug profile also summarized early Phase 1a findings, indicating that gastrointestinal AEs were the most common, while hematological events like neutropenia (4.6%) and anemia (12.3%) were less frequent and mostly low-grade, lending support to the CDK4-selective safety hypothesis.[11]

NCT06253195 (Study ID: BGB-43395-102)

• Official Title: "A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Chinese Patients With Advanced or Metastatic HR+/HER2- Breast Cancer and Other Solid Tumors".[5]
• Phase: 1a/1b.[5]
• Status: Actively recruiting participants as of March 20, 2025.[5] The study commenced in April 2024.[5]
• Purpose: Similar to NCT06120283, this study aims to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of BGB-43395 (monotherapy or combination), but is specifically enrolling Chinese participants.[5]
• Patient Population: Chinese participants (≥18 years) with locally advanced or metastatic solid tumors associated with CDK4 dependency (Phase 1a), including HR+/HER2- breast cancer. Phase 1b will focus on selected solid tumors, including HR+/HER2- breast cancer, with prior therapy and hormonal status requirements similar to those in NCT06120283.[5]
• Interventions: BGB-43395 as monotherapy or in combination with fulvestrant, letrozole, or other therapeutic partners.[5]
• Locations: Multiple study centers within China, including Beijing Cancer Hospital, Fujian Cancer Hospital, and Sun Yat Sen Memorial Hospital.[5]
• Estimated Enrollment: 78 participants, with an estimated study completion date of October 26, 2026.[5]

NCT06761898 (Study ID: BGB-43395-103)

• Purpose/Title: This is a Phase 1 pharmacokinetics trial being conducted in healthy volunteers in the USA. The study involves an oral tablet formulation of BGB-43395.[1] It is likely designed to assess different formulations of BGB-43395 and to evaluate the effect of food on its pharmacokinetic profile.[27]
• Phase: 1.[1]
• Status: Initiated on January 14, 2025.[1] Currently recruiting participants.[27]
• Patient Population: Healthy volunteers.[1]
• Primary Outcome Measures: Key pharmacokinetic parameters such as Cmax, AUC, and t1/2.
• Note: Some general clinical trial database snippets provided conflicting information for this NCT ID. However, specialized pharmaceutical intelligence databases [1] consistently link NCT06761898 to a BeiGene-sponsored Phase 1 PK study of BGB-43395 in healthy volunteers, and this information is considered more reliable for this report.

NCT06756932 (Study ID: BGB-21447-102)

• Official Title: "A Study to Assess the Safety and Tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in Combination With Fulvestrant, With or Without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in Adults With HR+/HER2- Metastatic Breast Cancer".[28]
• Phase: 1.[29]
• Status: Actively recruiting participants.[28]
• Purpose: The primary goal is to assess the safety and tolerability of the Bcl-2 inhibitor BGB-21447 when administered in combination with fulvestrant. One arm of the study will also include BGB-43395, evaluating a triplet combination.[28]
• Patient Population: Adults diagnosed with HR+/HER2- metastatic breast cancer who have received at least two prior lines of treatment for metastatic disease. This prior treatment must include endocrine therapy and a CDK4/6 inhibitor.[29]
• Interventions: Combination of BGB-21447 plus fulvestrant, with a cohort also receiving BGB-43395.[28]
• Locations: Australia.[1]

5.2 Pharmacokinetics and Pharmacodynamics (PK/PD) in Humans

Early pharmacokinetic and pharmacodynamic data are emerging from the ongoing Phase 1a portion of the NCT06120283 study, with initial safety and pharmacology findings presented at the SABCS in 2024.[10] Comprehensive PK parameters, including Cmax, Ctrough, AUC, and t1/2 for BGB-43395 and its metabolite(s), are being systematically collected in the Phase 1a/1b studies.[21] The dedicated healthy volunteer study (NCT06761898) is expected to provide crucial baseline PK data, including assessments of bioavailability and the impact of food on absorption.[1]

5.3 Target Indications in the Clinical Program

The clinical development program for BGB-43395 is primarily focused on:

• Metastatic HR+/HER2- breast cancer: This includes patients who are treatment-naïve in the metastatic setting as well as those who have progressed on prior therapies, including dual CDK4/6 inhibitors.[5] Exploratory efforts are underway in:
• Other advanced solid tumors with potential CDK4 dependency, such as ovarian cancer, endometrial cancer, and NSCLC.[4]
• HER2-positive breast cancer is also listed as an indication in Phase 1 trials according to AdisInsight, suggesting investigation in this subtype, likely in combination regimens.[1]

The clinical development strategy for BGB-43395 appears comprehensive and strategically designed. The multi-arm Phase 1a/1b studies allow for efficient dose finding and initial efficacy assessment in various contexts (monotherapy, combination with standard endocrine agents). Conducting parallel studies in different global regions, including a dedicated trial for Chinese patients (NCT06253195), facilitates broader data generation for regulatory submissions and addresses regional patient populations. The healthy volunteer PK study (NCT06761898) will provide foundational ADME (absorption, distribution, metabolism, and excretion) data, which is critical for understanding the drug's behavior in humans. Furthermore, the inclusion of BGB-43395 in a novel combination trial with a Bcl-2 inhibitor (NCT06756932) indicates an early exploration of synergistic opportunities and future therapeutic avenues.

A significant aspect of the clinical program is the focus on patients who have progressed after treatment with existing CDK4/6 inhibitors.[7] This addresses a critical unmet medical need, as resistance to current CDK inhibitors is a common challenge. The preclinical efficacy observed in a palbociclib-resistant PDX model [8] provides a strong rationale for this line of investigation. Success in this patient population would establish BGB-43395 as a valuable therapeutic option in a later-line setting. The concurrent exploration in diverse solid tumors beyond breast cancer [4] also reflects an ambition to expand the utility of BGB-43395, contingent on identifying CDK4 dependency as a predictive biomarker in these other malignancies.

The following table provides a consolidated overview of the key clinical trials involving BGB-43395:

Table 2: Overview of BGB-43395 Clinical Trials

NCT ID	BeiGene Study ID	Phase	Official Title (Abbreviated)	Key Indication(s)	Patient Population Focus	Status (as of latest snippet)	Key Objectives	Est. Enrollment	Key Interventions	Key Locations	Source Snippet(s)
NCT06120283	BGB-43395-101	1a/1b	BGB-43395 Alone or Combo in Metastatic HR+/HER2- BC & Other Advanced Solid Tumors	HR+/HER2- Breast Cancer (BC), Other Advanced Solid Tumors	Adults with advanced/metastatic CDK4-dependent tumors; prior therapy including CDK4/6i for BC	Recruiting (Apr 2025)	Safety, Tolerability, MTD/RDFE, PK, PD, Preliminary Antitumor Activity	79	BGB-43395 (oral, mono or combo with Fulvestrant/Letrozole)	Australia, USA, Global	6
NCT06253195	BGB-43395-102	1a/1b	BGB-43395 Alone or Combo in Chinese Pts with HR+/HER2- BC & Other Advanced Solid Tumors	HR+/HER2- BC, Other Advanced Solid Tumors	Chinese adults with advanced/metastatic CDK4-dependent tumors	Recruiting (Mar 2025)	Safety, Tolerability, MTD/RDFE, PK, PD, Preliminary Antitumor Activity	78	BGB-43395 (oral, mono or combo with Fulvestrant/Letrozole)	China	5
NCT06761898	BGB-43395-103	1	PK of BGB-43395 in Healthy Volunteers	Healthy Volunteers	Healthy adult volunteers	Recruiting (Jan 2025)	Pharmacokinetics, Food Effect	N/A	BGB-43395 (oral tablet)	USA	1
NCT06756932	BGB-21447-102	1	BGB-21447 (Bcl-2i) + Fulvestrant +/- BGB-43395 in HR+/HER2- Metastatic BC	HR+/HER2- Metastatic BC	Adults with HR+/HER2- metastatic BC, ≥2 prior lines for metastatic disease (incl. endocrine therapy & CDK4/6i)	Recruiting	Safety, Tolerability of combination	N/A	BGB-21447 + Fulvestrant +/- BGB-43395	Australia	1

6. Regulatory Status and Intellectual Property

BGB-43395 is currently in Phase 1 of clinical development.[1] As an investigational agent in early-stage trials, specific details regarding Investigational New Drug (IND) application acceptance dates from major regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) are not provided in the available research snippets. Similarly, there is no mention of BGB-43395 having received Orphan Drug designation or Fast Track status from these agencies at this juncture.[30]

Regarding intellectual property, BGB-43395 is identified as a New Molecular Entity (NME) originated and developed by BeiGene.[1] While specific patent application numbers (e.g., WO, US, EP series) or detailed claims covering the composition of matter, methods of synthesis, or methods of use for BGB-43395 are not explicitly detailed in the generally accessible portions of the provided snippets, the Synapse drug database indicates the existence of "100 Patents (Medical) associated with BGB-43395".[11] Access to the specifics of these patents, however, requires a login to the Synapse platform. General patent search results included in the research materials [8] did not yield direct and specific patent documents for BGB-43395's composition of matter or its primary uses. These general searches often yielded results for other BeiGene products (like zanubrutinib), discussed patent search systems themselves, or were related to different compounds or broader technological areas. Scientific disclosures, such as the abstract and poster presented at the San Antonio Breast Cancer Symposium (SABCS) in 2024 [8], typically follow the filing of patent applications to ensure intellectual property rights are secured.

The current regulatory standing of BGB-43395 as a Phase 1 NME is consistent with the standard trajectory for novel drug development. Special regulatory designations like Fast Track or Breakthrough Therapy are generally pursued once sufficient clinical data emerges to support claims of significant potential benefit in serious conditions or areas of unmet medical need. Given that HR+/HER2- breast cancer, a primary target indication, has several established therapies, BGB-43395 would need to demonstrate compelling differentiation in its early clinical trials to qualify for such expedited regulatory pathways. Orphan Drug designation would typically not apply to broader indications like HR+/HER2- breast cancer unless a very specific, rare sub-population within this group was being targeted initially.

For any novel pharmaceutical compound, particularly an NME developed by a major oncology-focused company like BeiGene, securing a robust and comprehensive intellectual property portfolio is a critical business imperative. This portfolio would be expected to include patents covering the composition of matter of BGB-43395, its methods of synthesis, various formulations, and its therapeutic uses. Such patent applications are typically filed early in the discovery and preclinical development phases to protect the innovation and ensure future market exclusivity. The reference in the Synapse database to numerous patents associated with BGB-43395 [11] strongly supports the existence of such a patent estate, even if the specific details are not available in the general search results provided. Accessing specialized patent databases or awaiting public disclosures from BeiGene would be necessary to obtain granular details of this IP portfolio.

7. Competitive Landscape

The development of BGB-43395 occurs within a competitive and evolving landscape for CDK inhibitors, particularly in the treatment of HR+/HER2- breast cancer.

7.1 Comparison with Existing Dual CDK4/6 Inhibitors

BGB-43395 is positioned to differentiate itself from the established class of dual CDK4/6 inhibitors, which includes palbociclib, ribociclib, and abemaciclib. The primary differentiating factor is its high selectivity for CDK4 over CDK6. This selectivity is hypothesized to translate into an improved safety profile, most notably a reduction in CDK6-mediated neutropenia, which is a common and often dose-limiting toxicity of the dual inhibitors.[8] By potentially mitigating this neutropenia, BGB-43395 aims to allow for more sustained target engagement of CDK4, which could lead to enhanced efficacy. Preclinical studies presented by BeiGene have suggested that BGB-43395 possesses superior potency against CDK4 and, in certain xenograft models, demonstrated greater tumor growth inhibition compared to palbociclib.[9]

7.2 Positioning Relative to Other Selective CDK4 Inhibitors

The field of selective CDK4 inhibitors is also emerging, with Pfizer's atirmociclib (PF-07220060) being a key competitor.[8] Atirmociclib is also designed for CDK4 selectivity with similar goals of improving tolerability and efficacy. Currently, atirmociclib appears to be further advanced in clinical development, with pivotal studies already underway.[10] However, in preclinical head-to-head comparisons reported by BeiGene, BGB-43395 was shown to achieve more potent inhibition of RB1 phosphorylation in cancer cell lines than atirmociclib.[8]

The concurrent development of BGB-43395 by BeiGene and atirmociclib by Pfizer signals a significant industry effort to develop a "best-in-class" selective CDK4 inhibitor. The aim is to offer a therapeutic agent that improves upon the first generation of dual CDK4/6 inhibitors by providing a better balance of efficacy and safety. Ultimate success in this competitive space will likely hinge on demonstrating a clear and clinically meaningful advantage. This could manifest as a significantly lower incidence of severe neutropenia, the ability to maintain dose intensity without frequent interruptions, superior efficacy in broad patient populations (including those who have progressed on prior dual CDK4/6 inhibitors), or novel activity in other CDK4-dependent tumor types.

Should both BGB-43395 and atirmociclib, or other selective CDK4 inhibitors, eventually reach the market, subtle but important differences in their clinical profiles could lead to market segmentation. For instance, variations in specific aspects of their safety profiles (e.g., gastrointestinal tolerability versus hematological effects), efficacy in particular patient subgroups (defined by biomarkers or prior treatment history), or differences in dosing schedules and convenience could influence physician and patient preference. Direct head-to-head clinical trial data comparing these selective inhibitors would be highly influential, although such trials between compounds from different companies are less common in early development. BeiGene's stated intention to conduct a head-to-head trial for one of its other oncology assets (BGB-16673, a BTK degrader) against a competitor [10] suggests a corporate willingness to engage in direct comparative studies if deemed strategically advantageous. The evolving data from ongoing clinical trials for both BGB-43395 and its competitors will be critical in shaping their future positioning and market potential.

8. Summary, Conclusions, and Future Directions

BGB-43395, an orally available small molecule developed by BeiGene, represents a focused effort to advance the therapeutic paradigm of CDK inhibition in oncology. It is engineered as a highly potent and selective inhibitor of CDK4, distinguishing itself from the established class of dual CDK4/6 inhibitors. The core rationale behind its development is the hypothesis that by selectively targeting CDK4 and sparing CDK6, BGB-43395 can mitigate CDK6-associated toxicities, most notably neutropenia. This improved tolerability is anticipated to enable more sustained and optimal CDK4 target engagement, potentially leading to enhanced anti-tumor efficacy.

Preclinical investigations have provided a strong foundation for this hypothesis, demonstrating BGB-43395's superior biochemical potency against CDK4 compared to existing agents, its high selectivity over CDK6 and other kinases, and robust downstream effects on cell cycle regulation and proliferation in relevant cancer cell lines. In vivo studies have further shown significant tumor growth inhibition, both as a monotherapy and in combination with endocrine therapy, including in a challenging palbociclib-resistant PDX model. Critically, these preclinical studies also reported a favorable safety profile, with a notable absence of concerning neutropenia, aligning with the drug's design principles. Early Phase 1 clinical data appear to corroborate these preclinical safety signals, with gastrointestinal effects being more common than significant hematological toxicities.[11]

The potential advantages of BGB-43395 are significant. An improved tolerability profile, particularly a reduction in severe neutropenia, could lead to fewer dose interruptions or reductions, allowing for more consistent drug exposure and potentially more durable clinical responses. The preclinical activity observed in a palbociclib-resistant model suggests that BGB-43395 might offer a therapeutic option for patients whose disease has progressed on currently available dual CDK4/6 inhibitors, addressing a growing unmet medical need. Furthermore, its activity in various CDK4-dependent cancer cell lines beyond breast cancer hints at a broader potential applicability, provided that CDK4 dependency can be effectively identified as a predictive biomarker in these other malignancies.

However, the path forward is not without challenges. BGB-43395 must demonstrate a clear and clinically meaningful superiority or differentiation over the well-entrenched dual CDK4/6 inhibitors, which are already standard of care in HR+/HER2- breast cancer. It also faces direct competition from other selective CDK4 inhibitors in development, such as Pfizer's atirmociclib, which is further ahead in clinical trials.[10] The bar for efficacy and safety in this therapeutic area is high, and managing expectations while navigating the complexities of late-stage clinical development will be crucial. Validating CDK4 dependency as a robust and practical biomarker for patient selection in tumors beyond breast cancer will also be essential for realizing its broader potential.

Looking ahead, the clinical development program for BGB-43395 is poised for significant activity. Completion of the ongoing Phase 1 studies (NCT06120283, NCT06253195, NCT06761898, and its involvement in NCT06756932) will be critical for establishing the recommended Phase 2 and Phase 3 doses, further characterizing the safety and PK/PD profiles, and gathering more extensive preliminary efficacy data. BeiGene has announced ambitious plans to advance BGB-43395 into Phase 3 trials for HR+/HER2- breast cancer, targeting both second-line and first-line settings, with potential initiation as early as the fourth quarter of 2025.[10] Continued exploration in other CDK4-dependent solid tumors will likely be guided by emerging clinical signals and ongoing biomarker research.

The aggressive development timeline and substantial sales projections articulated by BeiGene [10] underscore the company's strong belief in BGB-43395's potential to become a cornerstone oncology asset. Success in this endeavor would not only represent a significant commercial opportunity but also mark a meaningful advancement in the treatment of CDK4-driven cancers. The development of selective CDK4 inhibitors like BGB-43395 signifies an important evolution in the field of cell cycle inhibition, reflecting a transition from broader targeting of CDK4 and CDK6 to more refined and potentially more tolerable therapeutic strategies. This progression is driven by an enhanced understanding of the distinct biological roles of CDK4 versus CDK6 in both cancer pathogenesis and normal tissue homeostasis, a common theme in the ongoing quest for more precise and effective cancer therapies. The ultimate clinical and commercial success of BGB-43395 will depend on the strength and differentiation of its forthcoming clinical trial data in a competitive therapeutic landscape.

Works cited

1. BGB 43395 - AdisInsight - Springer, accessed May 19, 2025, https://adisinsight.springer.com/drugs/800076152
2. www.cancer.gov, accessed May 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cdk4-inhibitor-bgb-43395#:~:text=Upon%20oral%20administration%2C%20CDK4%20inhibitor,and%20inhibits%20tumor%20cell%20proliferation.
3. Definition of CDK4 inhibitor BGB-43395 - NCI Drug Dictionary - NCI, accessed May 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cdk4-inhibitor-bgb-43395
4. Clinical Trials Using CDK4 Inhibitor BGB-43395 - NCI, accessed May 19, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/cdk4-inhibitor-bgb-43395
5. BGB-43395 Alone or as Part of Combination Therapies in Chinese ..., accessed May 19, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06253195/bgb-43395-alone-or-as-part-of-combination-therapies-in-chinese-participants-with-hr-her2-breast-cancer-and-other-advanced-solid-tumors
6. Our Clinical trial: BGB-43395-101 | GenesisCare AU, accessed May 19, 2025, https://www.genesiscare.com/au/clinical-trials/listings/bgb-43395-101
7. BGB-43395 Alone or as Part of Combination Therapies in ..., accessed May 19, 2025, https://www.rarecancers.org.au/knowledgebase/clinical-trials/bgb-43395-alone-or-as-part-of-combination-therapies-in-participants-with-breast-cancer-and-other-advanced-solid-tumors/
8. Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and an, accessed May 19, 2025, https://www.beigenemedical.com/CongressDocuments/Zhu_BGB-43395_SABCS_Poster_2024.pdf
9. SABCS 2024 Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent - BeiGene Medical Information, accessed May 19, 2025, https://www.beigenemedical.com/CongressDocuments/Zhu_BGB-43395_SABCS_Abstract_2024.pdf
10. A pivotal push from BeiGene | ApexOnco - Clinical Trials news and ..., accessed May 19, 2025, https://www.oncologypipeline.com/apexonco/pivotal-push-beigene
11. BGB-43395 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 19, 2025, https://synapse.patsnap.com/drug/af552af0fd77484e94c9b8f253f6c020
12. BGB-43395 by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval, accessed May 19, 2025, https://www.pharmaceutical-technology.com/data-insights/bgb-43395-beigene-non-small-cell-lung-cancer-likelihood-of-approval/
13. U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene, accessed May 19, 2025, https://hkexir.beigene.com/news/us-patent-and-trademark-office-invalidates-pharmacyclics-patent-asserted-against-beigene/ee44eca2-9c83-4003-b0c6-476e3ecc56d8
14. BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates - BioSpace, accessed May 19, 2025, https://www.biospace.com/press-releases/beigene-announces-fourth-quarter-and-full-year-2024-financial-results-and-business-updates
15. BeiGene Announces First Quarter 2025 Financial Results and Business Updates, accessed May 19, 2025, https://www.businesswire.com/news/home/20250507583971/en/BeiGene-Announces-First-Quarter-2025-Financial-Results-and-Business-Updates
16. Pipeline - BeOne Medical Affairs | US - BeiMedPlus, accessed May 19, 2025, https://www.beimedplus.com/us/pipeline/
17. beigene.com, accessed May 19, 2025, https://beigene.com/wp-content/uploads/2025/03/Global-Clinical-Development-Pipeline-Feb-2025.pdf
18. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Clinical Research Trial Listing - CenterWatch, accessed May 19, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06120283/bgb-43395-alone-or-as-part-of-combination-therapies-in-participants-with-breast-cancer-and-other-advanced-solid-tumors
19. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06120283
20. 202406171 - Siteman Cancer Center, accessed May 19, 2025, https://siteman.wustl.edu/clinical-trial/202406171/
21. BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors - Carebox Connect, accessed May 19, 2025, https://connect.careboxhealth.com/en-US/trial/listing/460035
22. BeiGene BGB-43395-101 (Advanced Solid Tumors) | Duke Cancer Institute, accessed May 19, 2025, https://www.dukecancerinstitute.org/clinical-trials/beigene-bgb-43395-101-advanced-solid-tumors
23. BeiGene BGB-43395-101 (Advanced Solid Tumors) - Clinical Trial - Duke Health, accessed May 19, 2025, https://www.dukehealth.org/clinical-trials/directory/pro00114226
24. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors - BeiGene, accessed May 19, 2025, https://beigene.com/clinical-trials/bgb-43395-alone-or-as-part-of-combination-therapies-in-participants-with-breast-cancer-and-other-advanced-solid-tumors/
25. Carey Kernodle Anders - Duke University School of Medicine, accessed May 19, 2025, https://medschool.duke.edu/profile/carey-kernodle-anders
26. BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors - BeiGene, accessed May 19, 2025, https://beigene.com/clinical-trials/bgb-43395-alone-or-as-part-of-combination-therapies-in-chinese-participants-with-hr-her2-breast-cancer-and-other-advanced-solid-tumors/
27. BGB-43395 / BeiGene - Larvol Delta, accessed May 19, 2025, https://delta.larvol.com/Products/?ProductId=6dc11b5b-9bdc-4823-86f2-f2ab6e710d30
28. ANZCTR search results - Australian Clinical Trials, accessed May 19, 2025, https://www.australianclinicaltrials.gov.au/anzctr-search-results?condition_category=Cancer&condition_code=allðics_approval=Yes&recruitment_status=all&search_text=&page=243
29. BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone ..., accessed May 19, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-00365
30. QED Receives Fast Track Designation for Infigratinib | BridgeBio, accessed May 19, 2025, https://bridgebio.com/news/bridgebio-pharmas-qed-therapeutics-receives-fast-track-designation-for-infigratinib/
31. Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review | FDA, accessed May 19, 2025, https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
32. bgne-20241231 - SEC.gov, accessed May 19, 2025, https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/bgne-20241231.htm
33. U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene – NASDAQ (US) Website, accessed May 19, 2025, https://ir.beigene.com/news/U.S.-Patent-and-Trademark-Office-Invalidates-Pharmacyclics-Patent-Asserted-Against-BeiGene/ee44eca2-9c83-4003-b0c6-476e3ecc56d8%20%20%20%20%20
34. WO2017108781A1 - Abemaciclib form iv - Google Patents, accessed May 19, 2025, https://patents.google.com/patent/WO2017108781A1/tr
35. Full article: Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC) - Taylor & Francis Online, accessed May 19, 2025, https://www.tandfonline.com/doi/full/10.1080/14740338.2025.2495178?src=
36. WO2015084892A1 - Methods for treating b cell proliferative disorders - Google Patents, accessed May 19, 2025, https://patents.google.com/patent/WO2015084892A1/en
37. Cancer has no borders. Neither do we. - HKEXnews, accessed May 19, 2025, https://www.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042802970.pdf